Showing 701 - 720 results of 99,150 for search '(( 5 ((mg decrease) OR (a decrease)) ) OR ( 50 ((nn decrease) OR (teer decrease)) ))', query time: 1.29s Refine Results
  1. 701
  2. 702
  3. 703
  4. 704
  5. 705

    Fig 9 - by Wenping Dong (3854437)

    Published 2021
    Subjects:
  6. 706

    Fig 4 - by Wenping Dong (3854437)

    Published 2021
    Subjects:
  7. 707

    Fig 8 - by Wenping Dong (3854437)

    Published 2021
    Subjects:
  8. 708

    Fig 7 - by Wenping Dong (3854437)

    Published 2021
    Subjects:
  9. 709

    Fig 3 - by Wenping Dong (3854437)

    Published 2021
    Subjects:
  10. 710

    Fig 6 - by Wenping Dong (3854437)

    Published 2021
    Subjects:
  11. 711

    Doxorubicin (A) and Doxorubicinol (B) concentrations in the arterial plasma following the IP administration of 1.5 or 4.5 mg kg-1 Doxorubicin. by Sergio Fabris (799604)

    Published 2015
    “…(B) Significance compared to baseline for the 1.5 mg kg-1 dose is denoted by ✝ and 4.5 mg kg-1 by *. α Denotes a decrease (P<0.05) compared to 24 hours. β Denotes difference (P<0.05) between administered doses.…”
  12. 712
  13. 713
  14. 714

    Blockade of CB<sub>1</sub> receptors does not prevent the anandamide-induced decrease in locomotor activity and rearing. by Adriaan W. Bruijnzeel (2605954)

    Published 2016
    “…<p>Rats were treated with rimonabant (5 mg/kg, ip) and anandamide (10 mg/kg, ip) and horizontal (A) and vertical beam breaks (B) were assessed in the small open field. …”
  15. 715

    Plasma Lipoprotein(a) Levels Are Associated with Mild Renal Impairment in Type 2 Diabetics Independent of Albuminuria by Jennie Lin (671926)

    Published 2014
    “…Unadjusted and multivariable analyses of eGFR association with log-transformed lipid parameters in incremental linear and logistic regression models (with eGFR 90 mL/min/1.73 m<sup>2</sup> as a cut-point) were performed.</p><p>Results</p><p>Mild GFR impairment (eGFR 60–90 mL/min/1.73 m<sup>2</sup>, median urinary ACR 5.25 mg/g) was associated with higher log-transformed Lp(a) values (OR 1.17, p = 0.005) and with clinically atherogenic Lp(a) levels above 30 mg/dL (OR 1.35, p = 0.013) even after full adjustment for demographics, medications, metabolic parameters, and albuminuria. …”
  16. 716
  17. 717
  18. 718
  19. 719
  20. 720